Hinova Pharmaceuticals, Inc.SSE: 688302

(688302)"HINOVA PHARMACEUTICALS INC."Announcement on Voluntary Disclosure of Phase IIa Clinical Trial Data of HP515 Tablets Being Accepted as a Late-Breaking Abstract at the Annual Meeting of the American Association for the Study of Liver Diseases

· Issued by Hinova Pharmaceuticals, Inc. via Shanghai Stock Exchange

Filed with SSE · Stock code 688302 · · 3 pages · Chinese

Summary by 6ix AI

The company emphasizes that this development will not have a significant impact on its recent operating performance. The filing also outlines the potential risks and uncertainties associated with the ongoing clinical research and future market competition.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/688302hinova-pharmaceuticals-incannouncement-on-voluntary-disclosure-of-phase-iia-clinical-trial-data-of-hp515-tablets-being-accepted-as-a-late-breaking-abstract-at-the-annual-meeting-of-the-american-association-for-the-study-of-liver-diseases

Release

Announcement on Voluntary Disclosure of Phase IIa Clinical Trial Data of HP515 Tablets Being Accepted as a Late-Breaking Abstract at the Annual Meeting of the American Association for the Study of Liver Diseases

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Hinova Pharmaceuticals, Inc. on 6ix

Story so far

Earlier from Hinova Pharmaceuticals

All Hinova Pharmaceuticals news releases